Ligand Pharmaceuticals (LGND) Accounts Payables (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Accounts Payables of $5.3 million for Q1 2026, up 62.57% sequentially from $3.2 million in Q4 2025, and down 1.9% YoY from $5.4 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Accounts Payables (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Accounts Payables for 17 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Accounts Payables fell 1.9% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 1.9% YoY) and the FY2025 annual result came in at $3.2 million, down 38.12% from the prior year.
- Accounts Payables rose to $5.3 million in Q1 2026 per LGND's latest filing, from $3.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $19.2 million in Q2 2022 and troughed at $1.8 million in Q2 2024.
- A 5-year average of $6.3 million and a median of $5.3 million in 2026 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables plunged 84.42% in 2023, then jumped 378.75% in 2025.
- Over 5 years, Accounts Payables stood at $5.3 million in 2022, then plunged by 54.27% to $2.4 million in 2023, then jumped by 115.62% to $5.2 million in 2024, then plunged by 38.12% to $3.2 million in 2025, then surged by 62.57% to $5.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $5.3 million, $3.2 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 9.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.41 Mn |
| Mar 31, 2026 | 5.26 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | 8.58 Mn |
| Mar 31, 2025 | 5.37 Mn |
| Dec 31, 2024 | 5.23 Mn |
| Sep 30, 2024 | 4.69 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 2.48 Mn |
| Jun 30, 2023 | 9.58 Mn |
| Mar 31, 2023 | 6.14 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Sep 30, 2022 | 15.89 Mn |
| Jun 30, 2022 | 19.15 Mn |
| Mar 31, 2022 | 6.97 Mn |
| Dec 31, 2021 | 8.40 Mn |
| Sep 30, 2021 | 7.23 Mn |